retatrutide gip glp-1 glucagon receptor agonist PDB-101: Molecule of the Month: Agonists Retatrutide Api Triple Gip Glp-1

TrumpRx GLP-1 Deal Unlikely to Lower Canadian Prices, Experts Say A new US deal between the Trump administration, Eli Lilly and Novo Nordisk will start GLP-1 medications on the TrumpRx platform at roughly US$350 per month, dropping to US$245 US over the next two years, but Canadian patients are unlikely to see direct benefit from the cross-border program [Source: cbc.ca/news/health/ozempic-trumprx-cheaper-insurance-9.6970197]

Behavioral support (addressing eating behaviors, emotional triggers, psychological wellbeing) remains crucial for adherence and long-term success

Meeting these demands goes beyond incremental upgrades to existing infrastructure and instead calls for purpose-built capabilities and closer coordination between pharmaceutical companies and CDMOs

Nauck MA, Homberger E, Siegel EG, et al

Back Tashko (2024) 'History of GLP-1: From Discovery to Revolutionary Treatment'

For most patients, gastrointestinal symptoms settle down within a few weeks